Evidence map›Paper›PMID 37746553›Full record

ArticlePathology oncology research : POR2023

Active cancer as the main predictor of mortality for COVID-19 in oncology patients in a specialized center.

Freddy Villanueva-Cotrina, Juan Velarde, Ricardo Rodriguez, Alejandra Bonilla, Marco Laura, Tania Saavedra, Diana Portillo-Alvarez, Yovel Bustamante, Cesar Fernandez, Marco Galvez-Nino

Abstract read
In one paragraph

Article in Pathology oncology research : POR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Freddy Villanueva-CotrinaDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Juan VelardeDepartment of Infectious Diseases, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Ricardo RodriguezDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Alejandra BonillaDepartment of Radiodiagnosis, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Marco LauraDepartment of Radiodiagnosis, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Tania SaavedraDepartment of Critical Care Medicine, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Diana Portillo-AlvarezDepartment of Infectious Diseases, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Yovel BustamanteDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Cesar FernandezDepartment of Pathology, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru.
Marco Galvez-NinoProfessional School of Human Medicine, Universidad Privada San Juan Bautista, Lima, Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19NeoplasmsCOVID-19 TestingCross-Sectional StudiesHumansLactic AcidRetrospective StudiesLactic Acidactive cancerbiomarkersdeath prognosisimaging studySARS-CoV-2

Identifiers

PMID37746553
PMCPMC10511753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.